|
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial |
|
|
|
Titel: |
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial |
Auteur: |
Meng, Xiangrui Wu, Tao Hong, Yonggui Fan, Qingxia Ren, Zhonghai Guo, Yanzhen Yang, Xiuli Shi, Pei Yang, Jiamei Yin, Xianzhe Luo, Zhiquan Xia, Jin Zhou, Yue Xu, Mengli Liu, Enjie Jiang, Guozhong Li, Shenglei Zhao, Feng Ma, Chi Ma, Chuanxiang Hou, Zhiguo Li, Jing Wang, Junsheng Wang, Feng |
Verschenen in: |
The Lancet gastroenterology & hepatology |
Paginering: |
Jaargang 7 () nr. 3 pagina's 245-253 |
Jaar: |
2022 |
Inhoud: |
|
Uitgever: |
Elsevier Ltd |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|